Chemotherapy of malignant pleural mesothelioma

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 1, 2009, Pages 99-107

  Bertino, Pietro ^a,b   Carbone, Michele ^a   Pass, Harvey ^c  

^a UNIVERSITY OF HAWAII   (United States)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Mesothelioma; Novel agent; Therapeutic; Translational

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYANOCOBALAMIN; DOXORUBICIN; ERLOTINIB; FOLATE RECEPTOR; FOLIC ACID; GEMCITABINE; HOMOCYSTEINE; IMATINIB; MITOMYCIN; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; RALTITREXED; SORAFENIB; SUNITINIB; THALIDOMIDE; VINDESINE; ANTINEOPLASTIC AGENT; ASBESTOS;

AMINO ACID METABOLISM; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MEDLINE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; PANCREAS CANCER; PATIENT CARE; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SEPSIS; SOLID TUMOR; SURVIVAL TIME; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; MESOTHELIOMA; MORTALITY; MULTIMODALITY CANCER THERAPY; PHASE 3 CLINICAL TRIAL; PLEURA TUMOR; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASBESTOS; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MESOTHELIOMA; PALLIATIVE CARE; PLEURAL NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 65549164016     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802631285     Document Type: Review

References (63)

1. Kroczynska B, Cutrone R, Bocchetta M, et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc Natl Acad Sci USA 2006;103(38):14128-14133 (Pubitemid 44452991)
2. Carbone M, Pass HI. Evolving aspects of mesothelioma carcinogenesis: SV40 and genetic predisposition. J Thorac Oncol 2006;1(2):169-171 (Pubitemid 47164006)
3. Hodgson JT, McElvenny DM, Darnton AJ, et al. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 2005;92(3):587-593
4. Nurminen M, Karjalainen A, Takahashi K. Estimating the induction period of pleural mesothelioma from aggregate data on asbestos consumption. J Occup Environ Med 2003;45(10):1107-1115 (Pubitemid 37346127)
5. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995;345(8949)535-539
6. Leigh J, Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 2003;9(3)206-217
7. Price B, Ware A. Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003. Am J Epidemiol 2004;159(2):107-112
8. Attanoos RL, Gibbs AR. The pathology associated with therapeutic procedures in malignant mesothelioma. Histopathology 2004;45(4):393-397 (Pubitemid 39430644)
9. Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008;14(4):303-309
10. Nowak AK, Byrne MJ, Millward MJ, et al. Current chemotherapeutic treatment of malignant pleural mesothelioma. Expert Opin Pharmacother 2004;5(12):2441-2449 (Pubitemid 39646507)
11. Zellos LS, Sugarbaker DJ. Diffuse malignant mesothelioma of the pleural space and its management. Oncology (Williston Park) 2002;16(7):907-13; discussion 16-7, 19-20, 25
12. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85(1):265-72; discussion 72 (Pubitemid 350265805)
13. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005;353(15):1564-1573 (Pubitemid 41434635)
14. Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10(1 Pt 1):184-190 (Pubitemid 38114178)
15. Hartman DL, Gaither JM, Kesler KA, et al. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993;105(4):743-7; discussion 7-8 (Pubitemid 23127735)
16. Aelony Y, Yao JF, King RR. Prognostic value of pleural fluid pH in malignant epithelial mesothelioma after talc poudrage. Respiration 2006;73(3):334-339 (Pubitemid 43725792)
17. Chin YS, Yeghaian-Alvandi R, Noel M. Radiotherapy for the palliation of high-volume pleural effusion in malignant mesothelioma: case report. Palliat Med 2002;16(1):63-64 (Pubitemid 34262784)
18. Bohle AS, Kurdow R, Dohrmann P, Henne-Bruns D. Effective treatment of malignant pleural effusion: Thoracoscopic talcum pleurodesis and pleuro-peritoneal shunt. Dtsch Med Wochenschr 1999;124(12):341-345 (Pubitemid 29161938)
19. Ellis P, Davies AM, Evans WK, et al. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006;1(6):591-601 (Pubitemid 47181411)
20. Taylor P, Castagneto B, Dark G, et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol 2008;3(7):764-771
21. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38(2):111-121 (Pubitemid 35157753)
22. Fennell DA, Gaudino G, O'Byrne KJ, et al. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5(3):136-147 (Pubitemid 351330666)
23. Bueno R, Appasani K, Mercer H, et al. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;121(2):225-233 (Pubitemid 32150911)
24. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636-44 •• The first Phase III trial performed using palliative chemotherapy in mesothelioma. (Pubitemid 46606305)
25. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23(28):6881-6889 (Pubitemid 46260274)
26. Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6(4):363-373 (Pubitemid 32816541)
27. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21(8):1556-1561 (Pubitemid 46594110)
28. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008;19(2):370-373 (Pubitemid 351201722)
29. Kalmadi SR, Rankin C, Kraut MJ, et al. Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a Phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 2008;60(2):259-263 (Pubitemid 351609140)
30. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric Phase II study. Cancer 2003;97(11):2791-2797 (Pubitemid 36605147)
31. Simon GR, Verschraegen CF, Janne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a Phase II trial. J Clin Oncol 2008;26(21):3567-3572
32. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18(23):3912-3917
33. Fennell DA, C Steele JP, Shamash J, et al. Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma. Lung Cancer 2005;47(2):277-281 (Pubitemid 40089485)
34. O'Brien ME, Watkins D, Ryan C, et al. A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 2006;17(2):270-275
35. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26(10):1698-1704
36. Sorensen JB, Sundstrom S, Perell K, Thielsen AK. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol 2007;2(2):147-152 (Pubitemid 47181344)
37. Chen Y, Pandya K, Keng PC, et al. Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin Cancer Res 2003;9(3):969-975 (Pubitemid 36323699)
38. Rusch V, Saltz L, Venkatraman E, et al. A Phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 1994;12(6):1156-1163 (Pubitemid 24173928)
39. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22(17):3451-3457 (Pubitemid 41103650)
40. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999;117(1):54-63; discussion-5 (Pubitemid 29022249)
41. Weder W, Stahel RA, Bernhard J, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18(7):1196-1202 (Pubitemid 47244366)
42. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a Phase II trial. J Thorac Oncol 2006;1(4):289-295 (Pubitemid 47163979)
43. Ambrosini V, Rubello D, Nanni C, et al. Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma. Nucl Med Rev Cent East Eur 2005;8(2):111-115 (Pubitemid 43115961)
44. Alvarez JM, Ha T, Musk W, et al. Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy. J Thorac Cardiovasc Surg 2005;130(3):905-906 (Pubitemid 41265749)
45. Hoang CD, Zhang X, Scott PD, et al. Selective activation of insulin receptor substrate-1 and -2 in pleural mesothelioma cells: association with distinct malignant phenotypes. Cancer Res 2004;64(20):7479-7485 (Pubitemid 39372091)
46. Cacciotti P, Libener R, Betta P, et al. SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 2001;98(21):12032-12037 (Pubitemid 32959821)
47. Cacciotti P, Strizzi L, Vianale G, et al. The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor. Am J Respir Cell Mol Biol 2002;26(2):189-193 (Pubitemid 34107872)
48. Kothmaier H, Quehenberger F, Halbwedl I, et al. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 2008;63(4):345-351
49. Catalano A, Rodilossi S, Rippo MR, et al. Induction of stem cell factor/c-Kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells. J Biol Chem 2004;279(45):46706-46714 (Pubitemid 39518318)
50. Bertino P, Porta C, Barbone D, et al. Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax 2007;62(8):690-695 (Pubitemid 47235011)
51. Mathy A, Baas P, Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a Phase II trial. Lung Cancer 2005;50(1):83-86 (Pubitemid 41297473)
52. Porta C, Mutti L, Tassi G. Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma. Cancer Chemother Pharmacol 2007;59(1):149-150 (Pubitemid 44796113)
53. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004;31(2 Suppl 6):18-23 (Pubitemid 38879418)
54. Bertino P, Piccardi F, Porta C, et al. Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts. Clin Cancer Res 2008;14(2):541-8 • The first demonstration that mesothelioma in vitro cultured cells display the same chemo-resistance when injected in SCID mice.
55. Ohta Y, Shridhar V, Bright RK, et al. VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 1999;81(1):54-61 (Pubitemid 29415491)
56. Karrison T. Final analysis of a multi-centre, double blind, placebo controlled, randomized Phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):7526
57. Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 2008;113(4):808-814
58. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25(17):2406-2413 (Pubitemid 46999211)
59. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005;6510:4389-4400 (Pubitemid 40775678)
60. von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A Systematic Review of Phase II Trials of Thalidomide/Dexamethasone Combination Therapy in Patients with Relapsed or Refractory Multiple Myeloma. Eur J Haematol 2008;81(4):247-252
61. Biswas G, Narayanan P, Bhagwat R, et al. Thalidomide in primary peritoneal mesothelioma. J Surg Oncol 2006;93(5):434
62. Richly H, Henning BF, Kupsch P, et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006;17(5):866-873
63. Buckstein R, Meyer RM, Seymour L, et al. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol 2007;14(4):154-161